Recent and current Phase II clinical trials in endometrial cancer: review of the state of art

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2014-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2014.907272PMID 24717108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

  2015cited by this paper
• Metformin is associated with improved survival in endometrial cancer.

  2014cited by this paper
• Metformin use and endometrial cancer survival.

  2014cited by this paper
• Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.

  2014influential reference
• Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

  2014cited by this paper
• Integrated genomic characterization of endometrial carcinoma

  2013influential reference
• Hereditary gynaecological malignancies: advances in screening and treatment

  2013cited by this paper
• Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie.

  2013cited by this paper
• Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.

  2013influential reference
• Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer.

  2013cited by this paper
• Conservative treatment of early endometrial cancer

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Type I and II endometrial cancers: have they different risk factors?

  2013cited by this paper
• A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.

  2013influential reference
• A preoperative window study of metformin for the treatment of endometrial cancer.

  2013cited by this paper
• Endometrial cancer and a family history of cancer.

  2013cited by this paper
• New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway—The Devil Is in the Details

  2013cited by this paper
• Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC).

  2013cited by this paper
• Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2013cited by this paper
• The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

  2013cited by this paper
• Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

  2013cited by this paper
• Evaluation of treatment benefit: randomized controlled trials and population-based observational research.

  2013cited by this paper
• A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

  2013cited by this paper
• A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes.

  2013cited by this paper
• Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition In Vivo

  2013cited by this paper
• Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

  2013cited by this paper
• Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer.

  2012cited by this paper
• Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

  2012influential reference
• A phase II evaluation of docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus paraaortic irradiation for stage III endometrial cancer.

  2012cited by this paper
• Diabetes, metformin, and breast cancer in postmenopausal women.

  2012cited by this paper
• Weekly Paclitaxel-Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma

  2012cited by this paper
• A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

  2012influential reference
• Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

  2012influential reference
• Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.

  2012cited by this paper
• Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer

  2012cited by this paper
• Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma.

  2012influential reference
• Contemporary management of endometrial cancer.

  2012cited by this paper
• Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.

  2011influential reference
• Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma

  2011cited by this paper
• Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2011cited by this paper
• Understanding the benefit of metformin use in cancer treatment

  2011cited by this paper
• Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

  2011influential reference
• Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study

  2011cited by this paper
• A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.

  2011cited by this paper
• Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study

  2011influential reference
• Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248.

  2011cited by this paper
• A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.

  2011influential reference
• A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

  2011cited by this paper
• Recent advances in systemic therapy for advanced endometrial cancer

  2011influential reference
• Use of metformin and the risk of ovarian cancer: a case-control analysis.

  2011cited by this paper
• Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.

  2011cited by this paper
• Emerging therapeutic targets in endometrial cancer

  2011cited by this paper
• Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

  2011cited by this paper
• Adjuvant sequential chemo-radiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase II study of the NOGGO.

  2011cited by this paper
• A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma.

  2011cited by this paper
• Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma

  2010cited by this paper
• A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia.

  2010cited by this paper
• Hormonal therapy in advanced or recurrent endometrial cancer.

  2010influential reference
• Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.

  2010cited by this paper
• Molecular Profiling of Endometrial Malignancies

  2010cited by this paper
• Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

  2010cited by this paper
• Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).

  2010cited by this paper
• Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.

  2010cited by this paper
• PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

  2010cited by this paper
• Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer.

  2010cited by this paper
• Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

  2010cited by this paper
• Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.

  2010cited by this paper
• mTOR signaling and drug development in cancer

  2010cited by this paper
• A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

  2010cited by this paper
• Obesity and hormone therapy in breast cancer: an unfinished puzzle.

  2010cited by this paper
• Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010).

  2010cited by this paper
• Combination therapy with paclitaxel, carboplatin, and megesterol acetate for advanced-stage and recurrent endometrial carcinoma: A phase II study.

  2010cited by this paper
• Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

  2010cited by this paper
• 378 Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, Germany

  2010cited by this paper
• The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.

  2009cited by this paper
• Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.

  2009influential reference
• Phase 2 trial of mifepristone (RU‐486) in advanced or recurrent endometrioid adenocarcinoma or low‐grade endometrial stromal sarcoma

  2009influential reference
• Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

  2009cited by this paper
• Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair

  2009cited by this paper
• Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

  2009cited by this paper
• Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.

  2009cited by this paper
• A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.

  2009cited by this paper
• Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

  2009cited by this paper
• A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer

  2008cited by this paper
• The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.

  2008cited by this paper
• Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

  2008cited by this paper
• Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer.

  2008cited by this paper
• Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study

  2008cited by this paper
• Essential role for nuclear PTEN in maintaining chromosomal integrity.

  2007cited by this paper
• Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.

  2007influential reference
• Bevacizumab therapy in patients with recurrent uterine neoplasms.

  2007cited by this paper
• A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

  2007cited by this paper
• Carcinoma of the Corpus Uteri

  2006cited by this paper
• Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Hormone therapy in advanced and recurrent endometrial cancer: a systematic review

  2006cited by this paper
• Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

  2006cited by this paper
• Adjuvant therapy for early-stage endometrial cancer: a review

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper

• Liquid biopsy as a new era in endometrial cancer

  2024cites this paper
• NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

  2023influential citation
• Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer

  2023cites this paper
• Management of Endometrial Cancer

  2020cites this paper
• Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools

  2020cites this paper
• Targeted Therapy in Management of Endometrial Cancer

  2019cites this paper
• Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.

  2018cites this paper
• Identification of a Subset of Microsatellite-Stable Endometrial Carcinoma with High PD-L1 and CD8+ Lymphocytes

  2018cites this paper
• RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment

  2018cites this paper
• Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

  2017cites this paper
• Treatment strategies for endometrial cancer: current practice and perspective

  2017cites this paper
• Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.

  2016cites this paper
• Could S6K1 immunopositivity be used to distinguish early and advanced stages of endometrioid endometrial adenocarcinoma?

  2016cites this paper
• Current Progresses and Trends in the Development of Progesterone Receptor Modulators.

  2016cites this paper
• Targeting angiogenesis in endometrial cancer - new agents for tailored treatments

  2016cites this paper
• Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer

  2016cites this paper
• Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis.

  2016cites this paper
• New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?

  2016cites this paper
• Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.

  2014cites this paper